Alberto Monegro, MD
Pulmonary Disease · Buffalo, NYNPI 1073872552
Payments from drug & device makers
Across 19 payments — averaging $271.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Johnson & Johnson$1K
- Inspire Medical Systems, Inc.$144
- Mylan Specialty L.p.$57
- CSL Behring$29
- Sanofi$24
- plus $60 from 3 others
What the payments were for
- Travel & lodging$2,15742%
- Food & beverage$50910%
- Education$2,50048%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 6 | $3,532 |
| Johnson & Johnson | 6 | $1,319 |
| Inspire Medical Systems, Inc. | 1 | $144 |
| Mylan Specialty L.p. | 1 | $57 |
| CSL Behring | 1 | $29 |
| Sanofi | 1 | $24 |
| Paratek Pharmaceuticals, Inc. | 1 | $22 |
| Merck | 1 | $20 |
| Galvanize Therapeutics, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,496
- Monarch Platform$1,267
- Inspire$144
How this compares
$5,166 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 13 | $49,244 |
| Pirfenidone | 11 | $33,001 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $16,776 |
| HorizantGabapentin Enacarbil | 12 | $12,620 |
| Spiriva RespimatTiotropium Bromide | 24 | $12,256 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $7,551 |
| Modafinil | 13 | $7,264 |
| SymbicortBudesonide/Formoterol Fumarate | 28 | $6,737 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $5,275 |
| Qvar RedihalerBeclomethasone Dipropionate | 22 | $5,188 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,760 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,529 |
| Azithromycin | 18 | $147 |
| Prednisone | 39 | $142 |
| Fluticasone Propionate | 11 | $108 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Buffalo
- Carla FrederickBuffalo$972K
- Nashat RabadiBuffalo$613K
- M Jeffery MadorBuffalo$408K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.